{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:48:50Z","timestamp":1784872130343,"version":"3.55.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are frequently experienced by patients and may lead to severe symptoms and fatigue. However, the reporting patterns of these outcomes in IBD randomized controlled trials (RCTs) are not clear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched placebo-controlled phase 3 RCTs of advanced therapies in IBD and assessed the frequency and means of reporting EIM and fatigue data in these studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-three phase 3 RCTs for Crohn\u2019s disease (CD) (n\u2005=\u200516) or ulcerative colitis (UC) (n\u2005=\u200516) were identified between 2002 and 2023. While all trials (16\/16) in CD collected some EIM data, we could only ascertain 6\/16 (38%) collected EIM data in UC trials. Fewer than one-third (9\/32, 28%) reported EIM prevalence at baseline; fewer reported the improvement with active treatment (9%). Fatigue was measured in 20\/32 trials (63%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>EIM and fatigue data are inconsistently collected in RCTs of IBD. Standardizing collection methods across RCTs would provide greater insight on these agents and their efficacy in treating these manifestations of disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf009","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T12:32:27Z","timestamp":1737203547000},"source":"Crossref","is-referenced-by-count":3,"title":["Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-5678","authenticated-orcid":false,"given":"Tarun","family":"Chhibba","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Upstate Medical University , Syracuse, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N","family":"Ananthakrishnan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"2025012910402268200_CIT0001","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis","volume":"30","author":"Kilic","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025012910402268200_CIT0002","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2036.2010.04347.x","article-title":"Systematic review: fatigue in inflammatory bowel disease","volume":"32","author":"van Langenberg","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"2025012910402268200_CIT0003","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12325-018-0678-0","article-title":"Adalimumab reduces extraintestinal manifestations in patients with Crohn\u2019s disease: a pooled analysis of 11 clinical studies","volume":"35","author":"Louis","year":"2018","journal-title":"Adv Ther."},{"key":"2025012910402268200_CIT0004","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: a post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"2025012910402268200_CIT0005","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2025012910402268200_CIT0006","doi-asserted-by":"publisher","first-page":"17562848211005708","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025012910402268200_CIT0007","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med."},{"key":"2025012910402268200_CIT0008","doi-asserted-by":"publisher","first-page":"i036","DOI":"10.1093\/ecco-jcc\/jjab232.032","article-title":"OP33 effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe ulcerative colitis (UC): results from the UPA phase 3 programme","volume":"16","author":"Colombel","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025012910402268200_CIT0009","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomized trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"key":"2025012910402268200_CIT0010","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175","article-title":"Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn\u2019s disease: patient-reported outcomes of the CHARM trial","volume":"103","author":"Loftus","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"2025012910402268200_CIT0011","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA."},{"key":"2025012910402268200_CIT0012","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S2468-13(21)00297-1","article-title":"Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases","volume":"7","author":"Guillo","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025012910402268200_CIT0013","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","article-title":"Self-reported symptom burden in individuals with inflammatory bowel disease","volume":"10","author":"Farrell","year":"2016","journal-title":"J Crohns Colitis."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf009\/61491657\/jjaf009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/1\/jjaf009\/61491657\/jjaf009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/1\/jjaf009\/61491657\/jjaf009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T10:42:08Z","timestamp":1738147328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf009\/7960054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf009","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"jjaf009"}}